Literature DB >> 26740702

The use of dexmedetomidine continuous rate infusion for horses undergoing transvenous electrical cardioversion--A case series.

Charlotte Marly-Voquer1, Colin C Schwarzwald1, Regula Bettschart-Wolfensberger1.   

Abstract

Five horses were presented for treatment of atrial fibrillation by transvenous electrical cardioversion (TVEC). A dexmedetomidine infusion was administered for sedation during positioning of the cardioversion catheters, and continued during general anesthesia. Shocks were applied until return to sinus rhythm. Dexmedetomidine infusion provided excellent conditions for TVEC catheter placement and procedure.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26740702      PMCID： PMC4677613     

Source DB:  PubMed          Journal:  Can Vet J        ISSN： 0008-5286            Impact factor:   1.008


  24 in total

1.  Sedative, analgesic, and cardiovascular effects of levomedetomidine alone and in combination with dexmedetomidine in dogs.

Authors:  E Kuusela; O Vainio; A Kaistinen; S Kobylin; M Raekallio
Journal:  Am J Vet Res       Date:  2001-04       Impact factor: 1.156

2.  Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in the horse.

Authors:  M L Rezende; K N Grimsrud; S D Stanley; E P Steffey; K R Mama
Journal:  J Vet Pharmacol Ther       Date:  2014-07-28       Impact factor: 1.786

3.  Cardiopulmonary effects and pharmacokinetics of i.v. dexmedetomidine in ponies.

Authors:  R Bettschart-Wolfensberger; S L Freeman; I M Bowen; F S Aliabadi; R Weller; M Huhtinen; K W Clarke
Journal:  Equine Vet J       Date:  2005-01       Impact factor: 2.888

4.  Pharmacokinetics of medetomidine in ponies and elaboration of a medetomidine infusion regime which provides a constant level of sedation.

Authors:  R Bettschart-Wolfensberger; K W Clarke; O Vainio; F Aliabadi; D Demuth
Journal:  Res Vet Sci       Date:  1999-08       Impact factor: 2.534

5.  Influence of a constant rate infusion of dexmedetomidine on cardiopulmonary function and recovery quality in isoflurane anaesthetized horses.

Authors:  Miguel G Marcilla; Stijn Schauvliege; Stefanie Segaert; Luc Duchateau; Frank Gasthuys
Journal:  Vet Anaesth Analg       Date:  2012-01       Impact factor: 1.648

6.  Cardiovascular responses to transvenous electrical cardioversion of atrial fibrillation in anaesthetized horses.

Authors:  Stijn Schauvliege; Gunther van Loon; Dominique De Clercq; Lindsey Devisscher; Piet Deprez; Frank Gasthuys
Journal:  Vet Anaesth Analg       Date:  2009-07       Impact factor: 1.648

7.  Dexmedetomidine: a novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: a preliminary study.

Authors:  Constantinos Chrysostomou; Lee Beerman; Dana Shiderly; Donald Berry; Victor O Morell; Ricardo Munoz
Journal:  Anesth Analg       Date:  2008-11       Impact factor: 5.108

8.  Transvenous electrical cardioversion of equine atrial fibrillation: patient factors and clinical results in 72 treatment episodes.

Authors:  M K J McGurrin; P W Physick-Sheard; D G Kenney
Journal:  J Vet Intern Med       Date:  2008-05-02       Impact factor: 3.333

9.  Effect of butorphanol administration on cardiovascular parameters in isoflurane-anesthetized horses - a retrospective clinical evaluation.

Authors:  Erik H Hofmeister; Elizabeth B Mackey; Cynthia M Trim
Journal:  Vet Anaesth Analg       Date:  2007-08-13       Impact factor: 1.648

10.  Effects of a constant-rate infusion of dexmedetomidine on the minimal alveolar concentration of sevoflurane in ponies.

Authors:  M Gozalo-Marcilla; K Hopster; F Gasthuys; L Hatz; A E Krajewski; S Schauvliege
Journal:  Equine Vet J       Date:  2012-08-01       Impact factor: 2.888
View more
  1 in total

1.  Evaluation of the effect of different sedative doses of dexmedetomidine on the intestinal motility in clinically healthy donkeys (Equus asinus).

Authors:  Marwa Abass; Hussam Ibrahim; Hakan Salci; Mohamed A Hamed
Journal:  BMC Vet Res       Date:  2022-07-14       Impact factor: 2.792
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.